Impressive time-related influence of the Dutch screening programme on breast cancer incidence and mortality, 1975-2006
Corresponding Author
Johannes D.M. Otten
Department of Epidemiology, Biostatistics and Health Technology Assessment, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
National Evaluation Team for Breast Cancer Screening in The Netherlands (NETB), Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
Fax: +31-24-361-3505.
Department of Epidemiology, Biostatistics and Health Technology Assessment, Radboud University Nijmegen Medical Centre, P.O. BOX 9101, Internal 133, 6500 HB Nijmegen, The NetherlandsSearch for more papers by this authorMireille J.M. Broeders
Department of Epidemiology, Biostatistics and Health Technology Assessment, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
National Expert and Training Center for Breast Cancer Screening, Nijmegen, The Netherlands
National Evaluation Team for Breast Cancer Screening in The Netherlands (NETB), Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
Search for more papers by this authorJacques Fracheboud
Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
National Evaluation Team for Breast Cancer Screening in The Netherlands (NETB), Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
Search for more papers by this authorSuzie J. Otto
Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
National Evaluation Team for Breast Cancer Screening in The Netherlands (NETB), Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
Search for more papers by this authorHarry J. de Koning
Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
National Evaluation Team for Breast Cancer Screening in The Netherlands (NETB), Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
Search for more papers by this authorAndré L.M. Verbeek
Department of Epidemiology, Biostatistics and Health Technology Assessment, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
National Evaluation Team for Breast Cancer Screening in The Netherlands (NETB), Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
Search for more papers by this authorCorresponding Author
Johannes D.M. Otten
Department of Epidemiology, Biostatistics and Health Technology Assessment, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
National Evaluation Team for Breast Cancer Screening in The Netherlands (NETB), Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
Fax: +31-24-361-3505.
Department of Epidemiology, Biostatistics and Health Technology Assessment, Radboud University Nijmegen Medical Centre, P.O. BOX 9101, Internal 133, 6500 HB Nijmegen, The NetherlandsSearch for more papers by this authorMireille J.M. Broeders
Department of Epidemiology, Biostatistics and Health Technology Assessment, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
National Expert and Training Center for Breast Cancer Screening, Nijmegen, The Netherlands
National Evaluation Team for Breast Cancer Screening in The Netherlands (NETB), Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
Search for more papers by this authorJacques Fracheboud
Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
National Evaluation Team for Breast Cancer Screening in The Netherlands (NETB), Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
Search for more papers by this authorSuzie J. Otto
Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
National Evaluation Team for Breast Cancer Screening in The Netherlands (NETB), Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
Search for more papers by this authorHarry J. de Koning
Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
National Evaluation Team for Breast Cancer Screening in The Netherlands (NETB), Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
Search for more papers by this authorAndré L.M. Verbeek
Department of Epidemiology, Biostatistics and Health Technology Assessment, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
National Evaluation Team for Breast Cancer Screening in The Netherlands (NETB), Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
Search for more papers by this authorAbstract
The aim of this study was to assess changes in the trends in breast cancer mortality and incidence from 1975 to 2006 among Dutch women, in relation to the implementation of the national breast cancer screening programme. Screening started in 1989 for women aged 50–69 and was extended to women aged 70–75 years in 1998 (attendance rate approximately >80%). A joinpoint Poisson regression analysis was used to identify significant changes in rates over time. Breast cancer mortality rates increased until 1994 (age group 35–84), but thereafter showed a marked decline of 2.3–2.8% per annum for the age groups 55–64 and 65–74 years, respectively. For the age group of 75–84 years, a decrease started in the year 2001. In women aged 45–54, an early decline in breast cancer mortality rates was noted (1971–1980), which is ongoing from 1992. For all ages, breast cancer incidence rates showed an increase between 1989 and 1993, mainly caused by the age group 50–69, and thereafter, a moderate increase caused by age group 70–74 years. This increase can partly be explained by the introduction of screening. The results indicate an impressive decrease in breast cancer mortality in the age group invited for breast cancer screening, starting to show quite soon after implementation. © 2008 Wiley-Liss, Inc.
References
- 1 Ferlay J,Autier P,Boniol M,Heanue M,Colombet M,Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007; 18: 581–92.
- 2 Vainio H,Bianchini F. Efficacy of screening by conventional mammography. Breast cancer screening. Lyon: IARC Press, 2002. 91–102.
- 3 de Koning HJ. Mammographic screening: evidence from randomised controlled trials. Ann Oncol 2003; 14: 1185–9.
- 4 Stockton D,Davies T,Day N,McCann J. Retrospective study of reasons for improved survival in patients with breast cancer in east Anglia: earlier diagnosis or better treatment. BMJ 1997; 314: 472–5.
- 5 Coebergh JW,Crommelin MA,Kluck HM,van BM,van der HF,Verhagen-Teulings MT. [Breast cancer in southeast North Brabant and in North Limburg; trends in incidence and earlier diagnosis in an unscreened female population, 1975-1986]. Ned Tijdschr Geneeskd 1990; 134: 760–5.
- 6 Jatoi I,Miller AB. Why is breast-cancer mortality declining? Lancet Oncol 2003; 4: 251–4.
- 7 Fracheboud J,Otto SJ,van Dijck JA,Broeders MJ,Verbeek AL,de Koning HJ. Decreased rates of advanced breast cancer due to mammography screening in The Netherlands. Br J Cancer 2004; 91: 861–7.
- 8 NETB (National Evaluation Team for Breast cancer screening). NETB Interim Report 2006. Rotterdam: Department of Public Health, Erasmus MC, University Medical Center Rotterdam; 2006.
- 9[Internet] 2008 [cited 2008 February 25]. Available from: http://www.cbs.nl/en-GB/default.htm?Languageswitch-on.
- 10[Internet] 2008 [cited 2008 February 25]. Available from: http://www.ikcnet.nl/page.php?id-97.
- 11
Kim HJ,Fay MP,Feuer EJ,Midthune DN.
Permutation tests for joinpoint regression with applications to cancer rates.
Stat Med
2000;
19:
335–51.
10.1002/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.0.CO;2-Z CAS PubMed Web of Science® Google Scholar
- 12[Internet] 2008 [cited 2008 February 25]. Available from: http://srab.cancer.gov/joinpoint/.
- 13 Otto SJ,Fracheboud J,Looman CW,Broeders MJ,Boer R,Hendriks JH,Verbeek AL,de Koning HJ. Initiation of population-based mammography screening in Dutch municipalities and effect on breast-cancer mortality: a systematic review. Lancet 2003; 361: 1411–7.
- 14 Berry DA,Inoue L,Shen Y,Venier J,Cohen D,Bondy M,Theriault R,Munsell MF. Modeling the impact of treatment and screening on U.S. breast cancer mortality: a Bayesian approach. J Natl Cancer Inst Monogr 2006; 36: 30–6.
- 15 Vervoort MM,Draisma G,Fracheboud J,van de Poll-Franse LV,de Koning HJ. Trends in the usage of adjuvant systemic therapy for breast cancer in The Netherlands and its effect on mortality. Br J Cancer 2004; 91: 242–7.
- 16 Nab HW,Hop WC,Crommelin MA,Kluck HM,Coebergh JW. Improved prognosis of breast cancer since 1970 in south-eastern Netherlands. Br J Cancer 1994; 70: 285–8.
- 17 Louwman WJ,Voogd AC,van Dijck JA,Nieuwenhuijzen GA,Ribot J,Pruijt JF,Coebergh JW. On the rising trends of incidence and prognosis for breast cancer patients diagnosed 1975–2004: a long-term population-based study in southeastern Netherlands. Cancer Causes Control 2008; 19: 97–106.
- 18 Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. Lancet 1992; 339: 1–15.
- 19 Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. Lancet 1992; 339: 71–85.
- 20 Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351: 1451–67.
- 21 Levi F,Bosetti C,Lucchini F,Negri E,La VC. Monitoring the decrease in breast cancer mortality in Europe. Eur J Cancer Prev 2005; 14: 497–502.
- 22 de Koning HJ,Draisma G,Fracheboud J,de BA. Overdiagnosis and overtreatment of breast cancer: microsimulation modelling estimates based on observed screen and clinical data. Breast Cancer Res 2006; 8: 202.
- 23 Boer R,Warmerdam P,de KH,van OG. Extra incidence caused by mammographic screening. Lancet 1994; 343: 979.
- 24 NETB (National Evaluation Team for Breast cancer screening). National evaluation of mass screening for breast cancer in the Netherlands. Evaluation report XI (In Dutch with English summary). Rotterdam: Department of Public Health, Erasmus MC, University Medical Center Rotterdam; 2005.
- 25 Botha JL,Bray F,Sankila R,Parkin DM. Breast cancer incidence and mortality trends in 16 European countries. Eur J Cancer 2003; 39: 1718–29.
- 26 MacMahon B. Epidemiology and the causes of breast cancer. Int J Cancer 2006; 118: 2373–8.
- 27 de Jong-van den Berg LT,Faber A,van den Berg PB. HRT use in 2001 and 2004 in The Netherlands–a world of difference. Maturitas 2006; 54: 193–7.
Citing Literature
